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type A (BoNT/A) has been demonstrated in behavioral ani-
mal studies and clinical settings. It was shown that this
eﬀect is associated with toxin activity in CNS, however,
the mechanism is not fully understood. Substance P (SP)
is one of the dominant neurotransmitters in primary aﬀerent
neurons transmitting pain and itch. Thus, here we examined
association of SP-mediated transmission and BoNT/A
antinociceptive action by employing gene knock-
outs. Antinociceptive activity of intraplantarly (i.pl.)
injected BoNT/A was examined in mice lacking the gene
encoding for SP/neurokinin A (tac1/) or SP-preferred
receptor neurokinin 1 (tac1r/), compared to control
C57Bl/6 J wild type animals. BoNT/A action was assessed
in inﬂammatory pain induced by formalin and CFA, and neu-
ropathic pain induced by partial sciatic nerve ligation. BoNT/
A activity in CNS was examined by c-Fos and BoNT/A-
cleaved SNAP-25 immunohistochemistry. In wild type
mice, acute (formalin-evoked) and chronic pain (neuropathic
and inﬂammatory) was reduced by peripherally injected
BoNT/A. In tac1/ and tac1r/ knockout mice, BoNT/A
exerted no analgesic eﬀect. In control animals BoNT/A
reduced the formalin-evoked c-Fos expression in lumbar
dorsal horn, while in knockout mice the c-Fos expression
was not reduced. After peripheral toxin injection, cleaved
SNAP-25 occurred in lumbar dorsal horn in all animal geno-
types. BoNT/A antinociceptive activity is absent in animals
lacking the SP and neurokinin 1 receptor encoding genes, in
spite of presence of toxin’s enzymatic activity in central sen-
sory regions. Thus, we conclude that the integrity of SP-
ergic system is necessary for the antinociceptive activity
of BoNT/A.  2017 The Authors. Published by Elsevier Ltd
on behalf of IBRO. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).http://dx.doi.org/10.1016/j.neuroscience.2017.06.040
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associated protein 25.INTRODUCTION
Botulinum neurotoxin type A (BoNT/A), derived from
Clostridium botulinum, selectively enters neurons and
inhibits synaptic neurotransmitter exocytosis by
proteolytic cleavage of synaptosomal-associated protein
25 (SNAP-25) (Schiavo et al., 1993). Local paralysis with
low peripheral BoNT/A doses is the basis for treatment of
neuromuscular and autonomic disorders like spasticity,
dystonia, axillary hyperhidrosis, neurogenic bladder, etc.
(Jabbari, 2016). In addition, BoNT/A has been used in dif-
ferent chronic pain conditions: diabetic neuropathy,
trigeminal neuralgia, arthritis, low back pain, and chronic
migraine (review by Matak and Lackovic´, 2014). It was
suggested that BoNT/A reduces pain by inhibiting the
release of pro-nociceptive neurotransmitters like gluta-
mate, calcitonin gene-related peptide, and substance P
(SP), from primary sensory neurons (Go¨bel et al., 2001;
Freund and Schwartz, 2003). Initial animal data led to
hypothesis that BoNT/A exerts its antinociceptive activity
by preventing the sensory transmitter release in periphery
(Aoki, 2005). However, more recent data demonstrated
the necessity of axonal transport for BoNT/A antinocicep-
tive action (Bach-Rojecky and Lackovic´, 2009). Evidence
of toxin enzymatic activity in brainstem and spinal cord
sensory regions suggest that BoNT/A inhibits central pain
transmission (Matak et al., 2011).
SP is an 11-aminoacid neuropeptide present in
peripheral and central terminals of non-myelinated
primary sensory neurons. SP is encoded by tachykinin 1
(tac1) gene, which also encodes neurokinin A (NKA) by
alternate splicing (Steinhoﬀ et al., 2014). Actions of SP
are mainly mediated by neurokinin 1 receptor (NK1R),
encoded by tachykinin1 receptor (tac1r) gene. NK1R is
a G protein-coupled receptor which mediates stimulatory
eﬀects of SP in epithelial and mast cells in peripheral tis-
sue, as well as neurons and glia in CNS (Pinte´r et al.,
2014; Todd et al., 2002). In the brain, SP has been
involved in stress, anxiety, depression, emesis etc. In
the periphery, SP-ergic system is implicated in autonomic
functions such as cardiovascular responses, intestinal
motility, bladder functions, inﬂammation and transmission
of pain and itch (Mistrova et al., 2016). SP activates mast
cell degranulation and increases permeability of bloodons.org/licenses/by-nc-nd/4.0/).
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the peripheral tissue. In the spinal cord, SP is involved
in transmission of hyperalgesia and allodynia via NK1R
located at second order-sensory neurons (Pinte´r et al.,
2014; Todd et al., 2002).
BoNT/A may prevent the release of SP both in vitro
and in vivo (Welch et al., 2000; Ishikawa et al., 2000;
Lucioni et al., 2008; Carmichael et al., 2010; Filipovic´
et al., 2012). It prevents neurogenic plasma protein
extravasation in the rat hind-limb skin evoked by sciatic
nerve stimulation (Carmichael et al., 2010), and dural
plasma protein extravasation evoked by diﬀerent types
of trigeminal pain (Filipovic´ et al., 2012; Lackovic´ et al.,
2016). It was suggested that peripherally injected botuli-
num toxin serotype B (BoNT/B) prevents central SP
release (Marino et al., 2014; Ramachandran et al.,
2015). Although BoNT/A may prevent the SP transmis-
sion, the causal role of this eﬀect in the mechanism of
its antinociceptive action has not been assessed so far.
Thus, in the present study we examined the eﬀect of
BoNT/A on acute and chronic experimental pain in tac1
and tac1r homozygous mouse knockouts lacking SP
and NK1R.EXPERIMENTAL PROCEDURES
Animals & ethics statement
Experiments were performed on adult male mice lacking
the SP and NKA (tac1/), and the tachykinin receptor
NK1R (tac1r/) backcrossed for 8–10 generations to
the C57BL/6 J line. The tac1/ and tacr1/ mice were
generated as previously described (De Felipe et al.,
2000; Laird et al., 2000). Original breeding pairs of tac/
and tac1r/ were provided by Prof. John P. Quinn
(University of Liverpool, UK). C57Bl/6J mice were used
as wild type controls and the original breeding pairs were
purchased from Innovo Ltd. (Hungary). The animal
weights ranged from 25 to 28 g. The mice were bred at
the Department of Pharmacology and Pharmacotherapy
(University of Pe´cs, Hungary), provided with unlimited
access to standard mouse chow and drinking water, and
maintained under a 12-h light–dark cycle at 24–25 C
room temperature. Animal procedures were performed
according to European Communities Council Directive
(86/609/EEC) and recommendations of International
Association for the Study of Pain (Zimmerman, 1983),
and approved by the Ethics Committee on Animal
Research of University of Pe´cs. All eﬀorts were made to
reduce the number of animals used.BoNT/A treatment
BoNT/A (Botox, Allergan Inc, Irvine CA, USA) was
injected intraplantarly (i.pl.) into right hind paw pad of
conscious, restrained animals (20 ll of 0.9% saline-
diluted, using a 30-gauge needle). 1 unit (1 U) of BoNT/
A preparation contains 48 pg of puriﬁed botulinum
neurotoxin type A complex. The applied doses (0.2 and
0.4 U) were equivalent to previously employed rat doses
(7 and 15 U/kg) which did not induce any measurable
paralytic eﬀects (Cui et al., 2004; Bach-Rojecky andLackovic´, 2005). BoNT/A injected i.pl. did not impair the
hind limb toe spreading reﬂex. Normal 0/5 digit abduction
score upon tail suspension (Brown et al., 2013) was
observed in all animals.Neuropathic hyperalgesia model
Traumatic mononeuropathy was induced by partial sciatic
nerve ligation model introduced by Seltzer et al. (1990).
Animals were deeply anesthetized by i.p. ketamine-
xylazine (100 mg/kg ketamine and 5 mg/kg xylazine).
The right sciatic nerve was exposed at the mid-thigh level.
Under magnifying binoculars, approximately 1/3 to 1/2 of
the nerve diameter was tightly ligated with 9–0 non-
absorbable atraumatic suture. Seven days following the
nerve injury, BoNT/A (0.2 U) or saline was injected i.pl.
into the operated leg. Mechanical pain threshold was
behaviorally assessed by dynamic plantar esthesiometry
(Ugo Basile, Varese, Italy), as previously described
(Borbe´ly et al., 2013; Botz et al., 2013). In brief, mice were
allowed to accommodate in individual testing cubes with
wire mesh ﬂoor for 10 min. Thin metal probe with gradu-
ally increasing pressure (0–10 g) was applied to the plan-
tar surface of mouse hind-paw, until a lifting response was
elicited. The mechanonociceptive threshold was noted as
the pressure value in grams at which the animal withdrew
its paw. The cut-oﬀ value vas set to 10 g. Hyperalgesia
was determined as compared to the pre-treatment self-
control values. The contralateral, non-operated side
served as a control value at diﬀerent time points (7, 10
and 14 days after nerve injury).Adjuvant-induced chronic inﬂammatory hyperalgesia
model
Three days after BoNT/A (0.2U) administration, 20 ll of
complete Freund’s adjuvant (CFA, killed mycobacteria
suspended in paraﬃn oil, 1 mg/ml; Sigma, St. Louis,
MO, USA) was injected i.pl. into the ipsilateral hind paw.
Paw volume was measured by the displacement of
liquid induced by the hind paw immersion into the
chamber of plethysmometer (Ugo Basile, Varese, Italy).
The mechanonociceptive threshold was measured by
dynamic plantar esthesiometry. The mechanonociceptive
threshold and paw volume parameters obtained on the
contralateral, non-inﬂamed side served as control values
at diﬀerent time points (0, 1, 3 and 5 days after CFA
treatment).Formalin-evoked acute inﬂammatory nocifensive
behaviors, neuronal c-Fos activation and cleaved
SNAP-25 immunohistochemistry
In this experiment mice were treated with saline or 0.4 U
BoNT/A. This dose was chosen based on previously
employed BoNT/A dose (15 U/kg) which suppressed
formalin-evoked wide dynamic range neuronal excitation
and c-Fos expression in rats (Aoki, 2005). To determine
the acute inﬂammatory nocifensive behavior, formalin test
was used 7 days after the BoNT/A or saline treatment.
Conscious, restrained mice were injected i.pl. with 20 ll
of 0.9% saline-diluted 5% formalin (ipsilateral to BoNT/A
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quantitatively evaluated by the duration of paw liftings and
lickings in each 5-min examination period during 1 h
(Bo¨lcskei et al., 2005).The observation period was divided
into two phases: phase I (0–15 min) and phase II (15–
60 min). Phase I behavior represents a quick onset
response evoked by direct chemical stimulation of nerve
endings by formalin, while phase II represents delayed
inﬂammatory hyperalgesic behavior associated with
peripheral and central sensitization (Tjølsen et al.,
1992). Two hours after formalin injections, the animals
were deeply anesthetized with Euthasol (Virbac AH,
Fortworth, TX. USA) and perfused for immunohistochem-
istry with phosphate-buﬀered saline (PBS) followed by 4%
paraformaldehyde ﬁxative. Following the perfusion, the
lumbar spinal cord was excised and kept for 24 h in
15% sucrose + ﬁxative, followed by 30% sucrose in
PBS for 24 h. The samples were then removed and kept
on -80 C until further use.
The lumbar spinal cord L4 segment was cut with a
cryostat to 35-mm coronal slices, which were
immunostained for c-Fos by immunohistochemistry, as
previously described (Matak et al., 2014). In brief, free
ﬂoating sections were washed with PBS and blocked with
10% normal goat serum for 1 h. Sections were then incu-
bated with 1:500 rabbit anti-c-Fos primary antibody (sc-52,
Santa Cruz, Dallas, TX, USA) overnight at room tempera-
ture. The following day, sections were washed and incu-
bated with the secondary ﬂuorescent antibody goat-anti
rabbit Alexa Fluor 488 (Invitrogen, Carlsbad, CA, USA),
transferred onto the glass slides and coverslipped with
anti-fading agent. Tissue sections were then pho-
tographed with a ﬂuorescent microscope equipped with a
digital camera (Olympus, Tokyo, Japan). C-Fos-positive
neurons in ipsilateral and contralateral dorsal horns were
automatically counted in 5 randomly selected sections
per single animal using cellSens Dimension software
(Olympus, Tokyo, Japan), as previously described
(Matak et al., 2014). Cleaved SNAP-25 immunohisto-
chemistry was performed similarly as previously described
in rats (Matak et al., 2014). In brief, free ﬂoating sections
were washed with PBS and incubated 1 h in 10% normal
donkey serum, followed by polyclonal rabbit antibody toFig. 1. Time course of development of ipsilateral mechanical hyperalgesia fol
to BoNT/A treatment in wild type (C57BL/6 J), tac1/, and tac1r/ knockou
after BoNT/A; **-p< 0.01 in comparison to saline ipsi; n (mice/group) = 6–8;
by Bonferroni’s post hoc test).cleaved SNAP-25 (provided by Ornella Rossetto, Univer-
sity of Padua, Italy), 1:2000 dilution in 1% normal donkey
serum overnight at room temperature. The next day the
sections were washed and incubated in donkey anti rabbit
Alexa Fluor 555. Neuronal counterstain was similarly per-
formed with mouse anti-NeuN antibody (Millipore, Temec-
ula, CA, USA, 1:500 dilution overnight at 4 C) and donkey
anti-mouse Alexa Fluor 488 secondary antibody.Statistical analysis
The data are represented as mean ± SEM and analyzed
by one-way ANOVA or two-way ANOVA for repeated
measurements followed by Bonferroni’s post hoc test.
P< 0.05 was considered signiﬁcant.RESULTS
Deletion of tac1 and tac1r genes prevented the
reduction of neuropathic mechanical hyperalgesia by
BoNT/A
Seven days after sciatic nerve partial ligation injury,
animals developed ipsilateral mechanical hyperalgesia,
evident as approximately 35–40% reduction of the
mechanonociceptive thresholds compared to the
contralateral side (p< 0.001). Deletion of SP/NKA or
the NK1R-encoding genes did not aﬀect the
development of neuropathic mechanical hyperalgesia,
which was similar to WT mice. BoNT/A signiﬁcantly
reduced the hyperalgesia in wild type animals 7 days
after its injection. In contrast, BoNT/A did not counteract
the nerve ligation-evoked mechanical hyperalgesia in
the gene-deleted groups at any investigated time-points
(Fig. 1).Deletion of tac1 and tac1r genes prevented the
reduction of CFA-induced inﬂammatory mechanical
hyperalgesia by BoNT/A
In saline-treated animals, CFA-induced inﬂammation
decreased the mechanonociceptive thresholds in all
groups (p< 0.001 in comparison to contralateral non-
inﬂamed paws) (Fig. 1). BoNT/A pretreatment 3 dayslowing nerve injury induced by partial sciatic nerve ligation 7 days prior
t animals (time points indicate days after nerve injury operation / days
mean ± SEM, two-way ANOVA for repeated measurements followed
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mechanical hyperalgesia in wild type mice at days 1 and
3 post CFA (p< 0.001). In wild type animals, at day 6
the ipsilateral mechanical hyperalgesia started to
diminish, and the statistical diﬀerence between saline
and BoNT/A treatment was no longer observed. The
gene deletion of tac1 and tac1r did not alter the
development of mechanosensitivity, however, it
prevented the antinociceptive action of BoNT/A (Fig. 2).
Ipsilateral hind paw swelling resulting in an
approximately 2-fold increase of the hind paw volume
was observed 1, 3 and 6 days after CFA injection in all
genotypes (Fig. 3). BoNT/A treatment slightly attenuated
the development of edema formation in wild type and
tac1r-deleted mice on day 1 post CFA, but the eﬀect
was not signiﬁcant at later time points (Fig. 3).Tac1 and tac1r gene deletion prevents the BoNT/A
antinociceptive eﬀect on formalin-evoked
nocifensive behavior and neuronal activation
In wild type and knockout mice, formalin injection into the
hind paw induced biphasic nocifensive behavior andFig. 2. Time course of development of ipsilateral mechanical hyperalgesia fo
the hind paw at day 3 post BoNT/A pretreatment in wild type (C57BL/6 J), tac1
BoNT/A; ***-p< 0.001 in comparison to saline ipsi; n (mice/group) = 5–8, me
Bonferroni’s post hoc test).
Fig. 3. Time course of development of ipsilateral hindpaw edema following c
paw at day 3 post BoNT/A pretreatment in wild type (C57BL/6 J), tac1/, and
*-p< 0.05 in comparison to saline ipsi; **-p< 0.01 in comparison to saline ips
measurements followed by Bonferroni’s post hoc test).increased number of c-Fos-labeled neurons in the
ipsilateral spinal dorsal horn. BoNT/A treatment
signiﬁcantly reduced the phase II nocifensive behavior
and spinal c-Fos activation related to acute neurogenic
inﬂammatory mechanisms only in wild type animals
(Figs. 4–6). In tac1 and tac1r knockouts, BoNT/A
pretreatment aﬀected neither the phase II nocifensive
behavior, nor the activation of c-Fos (Figs. 5 and 6).
Cleaved SNAP-25-immunoreactive ﬁbers were observed
in ipsilateral lumbar spinal cord dorsal horn in all animal
genotypes (Fig. 7), as well as in spinal cord ventral horn
(not shown).DISCUSSION
In the present study we examined the inﬂuence of SP and
NK1R knockouts on the antinociceptive activity of BoNT/
A. We found that the deletion of genes encoding SP/
NKA and NK1R in mice prevented the BoNT/A
antinociceptive activity in acute and chronic
inﬂammatory pain, as well as neuropathic pain (Fig. 1,
Fig. 2, Fig. 4). These observations suggest thellowing complete Freund’s adjuvant (CFA) subcutaneous injection into
/, and tac1r/mice(time points indicate days after CFA / days after
an ± SEM, two-way ANOVA for repeated measurements followed by
omplete Freund’s adjuvant (CFA) subcutaneous injection into the hind
tac1r/mice (time points indicate days after CFA/days after BoNT/A;
i; n (mice/group) = 5–8, mean ± SEM, two-way ANOVA for repeated
Fig. 4. Lack of the eﬀect of BoNT/A on 5% formalin-evoked nocifensive behavior in tac1/ and tac1r/mice. Phase I behavior represents the total
duration of nocifensive behavior during ﬁrst 15 min following formalin injection, while phase II represents the duration of nocifensive behavior from
15 to 60 min following formalin challenge. (mean ± SEM. **-p< 0.01 in comparison to saline treatment; n (mice/group) = 4–5; mean ± SEM, one-
way ANOVA followed by Bonferroni’s post hoc test).
Fig. 5. Lack of eﬀect of BoNT/A on c-Fos expression in tac1/ and
tac1r/ mice. Neuronal activation was evoked by unilateral 5%
formalin injection into the hind paw, and assessed by c-Fos
immunohistochemistry. The image is representative of 4–5 animals
per group. Green punctate immunoﬂuorescent signal represents c-
Fos-expressing neuronal proﬁles. Scale bar = 250 mm.
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action of BoNT/A.
As the underlying mechanism of its analgesic activity it
was suggested that BoNT/A prevents peripheral
neurotransmitter and pro-inﬂammatory mediator release
at peripheral sensory nerve endings (Aoki, 2005). Morerecent observations support central site of BoNT/A
antinociceptive action: 1. bilateral eﬀect after unilateral
BoNT/A in mirror and polyneuropathic pain, 2. prevention
of BoNT/A antinociceptive eﬀect by disruption of axonal
transport within peripheral neurons, and 3. occurrence
of BoNT/A proteolytic products in central sensory regions
(Bach-Rojecky and Lackovic´, 2009; Favre-Guilmard
et al., 2009; Bach-Rojecky et al., 2010; Matak et al.,
2011; Matak et al., 2012; Favre-Guilmard et al., 2017).
Enzymatic activity of BoNT/A at central aﬀerent terminals
most likely involves prevention of sensory neurotransmit-
ter release (Matak and Lackovic´, 2014). Present data
suggest that BoNT/A analgesic eﬀect in mice is depen-
dent on the integrity of SP/NK1R-mediated nociceptive
transmission. Along with reduction of pain behavior,
BoNT/A antinociceptive action is accompanied by preven-
tion of neuronal activation and c-Fos expression in the
dorsal horn (Aoki, 2005; Drinovac et al., 2013). Thus, to
support the behavioral ﬁndings we assessed the c-Fos
expression evoked by formalin-induced pain. In accor-
dance with behavioral data, BoNT/A did not reduce the
dorsal horn c-Fos activation in tac1 and tac1r knockout
animals (Figs. 5 and 6). Since c-Fos activation is a reli-
able marker of increased nociceptive transmission from
primary aﬀerents to second order sensory neurons, these
results are in line with the possible BoNT/A interaction
with SP/NK1R transmission at the spinal level. Peripher-
ally applied BoNT/B reduced the internalization of NK1R
in the dorsal horn induced by formalin test or TRPV1 ago-
nist capsaicin in mice, indicative of inhibition of central SP
release (Marino et al., 2014; Ramachandran et al., 2015).
The lack of antinociceptive action of BoNT/A in knockout
mice might result from altered susceptibility of sensory
neurons to BoNT/A action, and possible lack of BoNT/A
enzymatic activity in CNS. Thus, we examined the occur-
rence of BoNT/A-mediated SNAP-25 cleavage in the
spinal dorsal horn, where the sensory neurons which
innervate the site of BoNT/A injection terminate centrally.
Individual ﬁbers expressing cleaved SNAP-25 occurred in
both wild type and knockout animals pretreated with
BoNT/A i.pl. (Fig. 7). This observation conﬁrms that
peripherally applied BoNT/A is enzymatically active in
Fig. 6. Lack of eﬀect of BoNT/A on c-Fos expression in tac1/ and tac1r/ mice. Neuronal activation was evoked by unilateral 5% formalin
injection into the hind paw and assessed by c-Fos immunohistochemistry. Number of c-Fos-expressing neurons was automatically counted in
ipsilateral (ipsi) and contralateral (cont) lumbar dorsal horn. (mean ± SEM. **-p< 0.01 in comparison to saline treatment; n (mice/group) = 4–5;
mean ± SEM, one-way ANOVA followed by Bonferroni’s post hoc test).
Fig. 7. Occurrence of individual BoNT/A-cleaved SNAP-25 (cSNAP-25) immunoﬂuorescent ﬁbers
in dorsal horn of i.pl. BoNT/A-injected wild type and tac1/ and tac1r/ mice. Red ﬂuorescent
ﬁbers (indicated by arrow heads) represent cleaved SNAP-25, while green staining represents
neurons (NeuN marker). Scale bar = 20 mm. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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in SP/NKA and NK1R knockouts.
In the CFA-induced hind paw inﬂammation, BoNT/A
attenuated the edema formation in wild type and NK1R
knockout mice at day 1 post CFA treatment, while at
later time points the eﬀect was not signiﬁcant (Fig. 3).
Since the BoNT/A anti-inﬂammatory action does not
parallel the time-course of its antinociceptive action
(Figs. 2 and 3), these data do not support causal
association of peripheral anti-inﬂammatory actions of
BoNT/A in its antinociceptive eﬀect. In line with presentobservation carrageenan- or
capsaicin-induced hind paw
inﬂammatory hyperalgesia, the BoNT/
A antinociceptive eﬀect was not
associated with detectable anti-
inﬂammatory eﬀect (Bach-Rojecky
and Lackovic´, 2005; Bach-Rojecky
et al., 2008; Favre-Guilmard et al.,
2009). Human studies involving exper-
imental inﬂammatory pain reported
variable results: BoNT/A reduced the
pain and vasomotor responses evoked
by capsaicin and glutamate in human
trigeminal area (Gazerani et al., 2006,
2009; da Silva et al., 2014), while in
studies involving capsaicin application
to the forearm skin, the results were
divergent (Tugnoli et al., 2007;
Schulte-Mattler et al., 2007; Voller
et al., 2003). In a recent large multicen-
tric study it was shown that BoNT/A
beneﬁcial action in peripheral neuro-
pathic pain was not associated with
reduction of CGRP and SP peptide
concentration in patient skin biopsy
samples (Attal et al., 2016).
In present experiments, the
antinociceptive eﬀect of BoNT/A in
neuropathic pain (Fig. 1) seems
modest compared to the eﬀect in CFA
or formalin-induced inﬂammatory pain
(Fig. 2, Fig. 4). We observed low
reduction of pain threshold induced byneuropathy (only 35–40%), and inability of BoNT/A to
fully restore the initial mechanical pain threshold
(Fig. 1). This result is in line with other studies which
report modest eﬀect of BoNT/A in chronic constriction
injury (CCI)-induced neuropathic pain in mice (Marinelli
et al., 2010; Mika et al., 2011; Vacca et al. 2013). We
did not assess the eﬀect of BoNT/A beyond day 7 after
peripheral toxin treatment, however, the eﬀect of BoNT/
A in previous mice studies was prolonged, and did not
increase signiﬁcantly with time (Marinelli et al., 2010;
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BoNT/A on nerve injury-induced mechanical hyperalge-
sia, in comparison to carrageenan or diabetic
neuropathy-evoked mechanical hyperalgesia, was
observed in rats (Bach-Rojecky et al., 2010; Drinovac
et al., 2013; Favre-Guilmard et al., 2017). It was specu-
lated that this might be associated with diﬀerent neuro-
chemical mediators involved in pain of diﬀerent origins
(Favre-Guilmard et al., 2017). In the CFA-evoked inﬂam-
matory pain model BoNT/A eﬀect was slightly more pro-
nounced compared to neuropathic pain (Fig. 2). On day
6 following the CFA treatment, the mechanical pain
thresholds in control animals started to recover, and the
antinociceptive eﬀect of BoNT/A was no longer statisti-
cally signiﬁcant. Lack of signiﬁcant action of BoNT/A on
day 6 post CFA was probably due to recovery of pain
threshold in control animals, rather than seemingly short
duration of BoNT/A action.
In summary, 1.) gene knockout of SP and NK1R has
no major eﬀect on pain sensitivity in diﬀerent models
(Figs. 1, 2, 4), 2.) we found the evidence of BoNT/A
enzymatic activity in CNS (Fig. 7), however 3.) BoNTA
had no antinociceptive eﬀect in these gene knockouts
(Fig. 1, 2, 4, and 6). It is widely accepted that SP and
NK1R are one of the key elements in transmission of
pain. In support of this, NK1R antagonists prevent pain
and hyperalgesia in rodent pain models (Lee and Kim,
2007; Cumberbatch et al., 1998; King et al., 2000). How-
ever, in our study we found that deletion of SP/NKA and
NK1R did not change sensitivity to pain in comparison
to control animals (Figs. 1, 2 and 6). The lack of eﬀect
of tac1 and tac1r knockout is in line with previous behav-
ioral observations. In partial sciatic nerve ligation neu-
ropathy, knockout and wild-type mice exhibited similar
spontaneous pain-related behavior, mechanical and cold
allodynia, and mechanical hyperalgesia (Cao et al.,
1998; Martinez-Caro and Laird, 2000; Botz et al., 2013).
Lack of the eﬀect of tac1 gene knockout was shown in
model of CFA-induced pain inﬂammation, as well as
formalin test (Cao et al., 1998). Those observations
suggest that, at least in knockout animals, SP and
NK1R are dispensable for the development of mechanical
hyperalgesia. On the other hand, in normal wild-type
animals, SP-NK1R system is actively participating in the
pain control and can be targeted pharmacologically with
BoNT/A or NK1R antagonists. Key diﬀerence between
pharmacological manipulation and gene knockouts is
that pharmacological treatment is limited in duration.
Thus, we speculate that the permanent deletion of tac1
and tac1r genes leads to change in neuronal plasticity
and/or development of alternative pain transmission
mechanisms insensitive to BoNT/A.
As discussed previously, the eﬀect of tac1 and tac1r
knockout on nociceptive thresholds and development of
mechanical hypersensitivity is very similar in examined
experimental types of pain. This could be due to the fact
that NK1R is the dominant receptor which mediates SP
eﬀects on pain, thus, the eﬀects exerted by knockout of
either the neurotransmitter, or its receptor, are similar.
However, in a model of chronic systemic arthritis
evoked by repeated CFA challenge, some subtlediﬀerences in mechanical pain thresholds occur with a
delay (Borbe´ly et al., 2013). Eleven days following the
pain induction, the mechanical hyperalgesia becomes
smaller in tac1r knockout animals while in tac1 knockouts
it is not signiﬁcantly reduced in comparison to wild type
(Borbe´ly et al., 2013).CONCLUSION
BoNT/A antinociceptive activity is dependent on integrity
of SP/NKA and NK1R.
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